Xolair loe?

What is Xolair used to treat?

Xolair, also known as Omalizumab, is an injectable medication used primarily to treat moderate to severe asthma and chronic spontaneous urticaria (hives). It's also used off-label for treating other conditions like eosinophilic esophagitis and atopic dermatitis [1].

How does Xolair work?

Xolair works by blocking the action of immunoglobulin E (IgE), a protein that plays a role in triggering allergic responses and asthma symptoms. By reducing IgE levels in the blood, Xolair can help alleviate symptoms associated with allergic asthma and hives [2].

Is Xolair a biologic?

Yes, Xolair is a recombinant humanized IgG1 monoclonal antibody biologic, which means it's made using genetic engineering techniques and is designed to mimic the structure of a human antibody [3].

What are some benefits of Xolair?

Xolair has been shown to effectively reduce asthma symptoms and improve quality of life for many patients. It's particularly useful for those who don't respond well to inhaled corticosteroids or other asthma medications [4].

How long does it take for Xolair to work?

Symptoms may start to improve within a few weeks of starting treatment, but full effect may take several months to develop [5].

Where can I learn more about Xolair?

To learn more about Xolair, visit the official website, consult with your healthcare provider, or explore trusted resources like the National Institutes of Health (NIH) or the European Medicines Agency (EMA) [6].

DrugPatentWatch.com:

For more information on Xolair patents, exclusivity, and market expiration dates, visit DrugPatentWatch.com [7].

Sources:

[1] - National Institutes of Health. (n.d.). Omalizumab (Xolair).
[2] - European Medicines Agency. (n.d.). Xolair (omalizumab).
[3] - Genentech. (n.d.). Xolair (omalizumab).
[4] - Asthma and Allergy Foundation of America. (n.d.). Xolair (Omalizumab).
[5] - Novartis Pharmaceuticals Corporation. (n.d.). Xolair (omalizumab).
[6] - National Institutes of Health. (n.d.). ClinicalTrials.gov - Search for omalizumab trials.
[7] - DrugPatentWatch.com. (n.d.). Omalizumab (Xolair) patents and exclusivity.